Goldman Sachs
IRWD icon

Goldman Sachs’s Ironwood Pharmaceuticals IRWD Stock Holding History

Goldman Sachs’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-150,086
Closed -$1.94M – 5825
2018
Q1 		$1.94M Hold
150,086
– – ﹤0.01% 3626
2017
Q4 		$1.88M Buy
+150,086
New +$1.96M ﹤0.01% 3847
2016
Q1 		– Sell
-82,267
Closed -$799K – 7191
2015
Q4 		$799K Sell
82,267
-37,133
-31% -$359K ﹤0.01% 4506
2015
Q3 		$1.04M Buy
119,400
+1,194
+1% +$11.1K ﹤0.01% 4438
2015
Q2 		$1.19M Buy
+118,206
New +$1.37M ﹤0.01% 4373
2014
Q1 		– Sell
-119,400
Closed -$1.16M – 6841
2013
Q4 		$1.16M Sell
119,400
-119,400
-50% -$1.07M ﹤0.01% 4595
2013
Q3 		$2.37M Sell
238,800
-71,640
-23% -$703K ﹤0.01% 3756
2013
Q2 		$2.58M Buy
+310,440
New +$3.76M ﹤0.01% 3454

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs's IRWD Position: Q2 2026 in Review

Goldman Sachs increased its Ironwood Pharmaceuticals (IRWD) stake by 23% in Q2 2026, buying an estimated $2.4M and bringing the position to 3,313,808 shares worth $14M. The position accounts for ﹤0.01% of the portfolio, ranked #2970.

Goldman Sachs first reported a position in IRWD in Q2 2013 and has held it in 53 quarters since. The position peaked at $40.2M in Q3 2021. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Goldman Sachs held 3,313,808 shares of Ironwood Pharmaceuticals worth $14M as of Q2 2026.
  • Goldman Sachs bought 623,174 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $2.4M.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2970 holding.
  • Goldman Sachs first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Goldman Sachs's Ironwood Pharmaceuticals position peaked at $40.2M in Q3 2021.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.